NOVELION THERAPEUTICS INC.
NVLN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NVLN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
—
Cash Runway
—
Lead Asset
juxtapid (Approved)
Next Catalyst
—
Financial data as of Mar 31, 2019.
Tracking 1 pipeline candidate for NOVELION THERAPEUTICS INC..
Run NOVELION THERAPEUTICS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NOVELION THERAPEUTICS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $8M · Net income -$32M · Debt/OCF 0.7×
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is NOVELION THERAPEUTICS INC.'s lead drug candidate?
NOVELION THERAPEUTICS INC.'s most advanced tracked candidate is juxtapid (Approved).
Who is the CEO of NOVELION THERAPEUTICS INC.?
Ben Harshbarger Interim is the chief executive officer of NOVELION THERAPEUTICS INC. (NVLN).
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.